Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Sci Total Environ ; 607-608: 676-682, 2017 Dec 31.
Artigo em Inglês | MEDLINE | ID: mdl-28709102

RESUMO

Bisphenol A (BPA) has caused widespread concern among scholars as a result of its estrogenic toxicity. It exists mainly in natural waters, sediments, and soil, as well as sewage and wastewater sludge. Considering that BPA is a common environmental pollutant that is removed along with chemical oxygen demand (COD), nitrogen, and phosphorus in drainage treatment systems, it is important to research the fate of BPA in sewage treatment systems. In this research, laboratory batch experiments on soil degradation and adsorption were conducted with 14C-BPA, aiming to discuss the transport and degradation characteristics of BPA in both simulated facilities and a soil trench. Based on the experimental results, the Freundlich model could be applied to fit the isothermal adsorption curve of the BPA in soil. A low mobility characteristic of BPA was discovered. The mineralization rate of BPA was fast and that of the reaction showed small fluctuations. After degradation, 21.3 and 17.7% of the BPA groups (the experimental group treated with ammonia oxidase (AMO) inhibitor and the control group) were converted into 14CO2, respectively. This indicates that the nitrification and degradation of BPA had a certain competitive relationship. Besides, nitrification did not significantly affect the soil residue of BPA. Through the soil trench test, the average removal rate of BPA in the soil trench was 85.5%. 14CO2 was discharged via the mineralization of BPA, accounting for 2.5% of the initial input. BPA easily accumulated in the bottom soil of the soil trench. BPA and its metabolites in the effluent accounted for 14.5% of the initial dosage. The residual extractable BPA and its metabolites in the soil accounted for 51.3%, and the remaining part of the unextractable residue represented 19.8% of the initial radioactive dosage.

2.
PLoS One ; 8(9): e74381, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24058556

RESUMO

BACKGROUND: The widespread use of clopidogrel alone or in combination with aspirin may result in gastrointestinal mucosal injury, clinically represented as recurrent ulceration and bleeding complications. Our recent work suggested that clopidogrel significantly induced human gastric epithelial cell (GES-1) apoptosis and disrupted gastric mucosal barrier, and that a p38 MAPK inhibitor could attenuate such injury. However, their exact mechanisms are largely unknown. METHODS: The GES-1 cells were used as a model system, the effects of clopidogrel on the whole gene expression profile were evaluated by human gene expression microarray and gene ontology analysis, changes of the mRNA and protein expression were determined by real-time PCR and Western blot analysis, and cell viability and apoptosis were measured by MTT assay and flow cytometry analysis, respectively. RESULTS: Gene microarray analysis identified 79 genes that were differentially expressed (P<0.05 and fold-change >3) when cells were treated with or without clopidogrel. Gene ontology analysis revealed that response to stress and cell apoptosis dysfunction were ranked in the top 10 cellular events being affected, and that the major components of endoplasmic reticulum stress-mediated apoptosis pathway - CHOP and TRIB3- were up-regulated in a concentration- and time-dependent manner when cells were treated with clopidogrel. Pathway analysis demonstrated that multiple MAPK kinases were phosphorylated in clopidogrel-treated GES-1 cells, but that only SB-203580 (a p38-specific MAPK inhibitor) attenuated cell apoptosis and CHOP over-expression, both of which were induced by clopidogrel. CONCLUSIONS: Increased endoplasmic reticulum stress response is involved in clopidogrel-induced gastric mucosal injury, acting through p38 MAPK activation.


Assuntos
Apoptose/efeitos dos fármacos , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Células Epiteliais/metabolismo , Células Epiteliais/patologia , Estômago/patologia , Ticlopidina/análogos & derivados , Apoptose/genética , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Clopidogrel , Análise por Conglomerados , Regulação para Baixo/efeitos dos fármacos , Regulação para Baixo/genética , Estresse do Retículo Endoplasmático/genética , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/enzimologia , Perfilação da Expressão Gênica , Humanos , Imidazóis/farmacologia , Anotação de Sequência Molecular , Análise de Sequência com Séries de Oligonucleotídeos , Piridinas/farmacologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase em Tempo Real , Ticlopidina/farmacologia , Regulação para Cima/efeitos dos fármacos , Regulação para Cima/genética , Proteínas Quinases p38 Ativadas por Mitógeno/antagonistas & inibidores , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo
3.
World J Gastroenterol ; 19(23): 3658-64, 2013 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-23801869

RESUMO

AIM: To investigate the expression patterns of long non-coding RNAs (lncRNAs) in gastric cancer. METHODS: Two publicly available human exon arrays for gastric cancer and data for the corresponding normal tissue were downloaded from the Gene Expression Omnibus (GEO). We re-annotated the probes of the human exon arrays and retained the probes uniquely mapping to lncRNAs at the gene level. LncRNA expression profiles were generated by using robust multi-array average method in affymetrix power tools. The normalized data were then analyzed with a Bioconductor package linear models for microarray data and genes with adjusted P-values below 0.01 were considered differentially expressed. An independent data set was used to validate the results. RESULTS: With the computational pipeline established to re-annotate over 6.5 million probes of the Affymetrix Human Exon 1.0 ST array, we identified 136053 probes uniquely mapping to lncRNAs at the gene level. These probes correspond to 9294 lncRNAs, covering nearly 76% of the GENCODE lncRNA data set. By analyzing GSE27342 consisting of 80 paired gastric cancer and normal adjacent tissue samples, we identified 88 lncRNAs that were differentially expressed in gastric cancer, some of which have been reported to play a role in cancer, such as LINC00152, taurine upregulated 1, urothelial cancer associated 1, Pvt1 oncogene, small nucleolar RNA host gene 1 and LINC00261. In the validation data set GSE33335, 59% of these differentially expressed lncRNAs showed significant expression changes (adjusted P-value < 0.01) with the same direction. CONCLUSION: We identified a set of lncRNAs differentially expressed in gastric cancer, providing useful information for discovery of new biomarkers and therapeutic targets in gastric cancer.


Assuntos
Biomarcadores Tumorais/genética , Perfilação da Expressão Gênica , RNA Longo não Codificante/genética , Neoplasias Gástricas/genética , Biologia Computacional , Mineração de Dados , Bases de Dados de Ácidos Nucleicos , Éxons , Perfilação da Expressão Gênica/métodos , Humanos , Modelos Lineares , Estadiamento de Neoplasias , Análise de Sequência com Séries de Oligonucleotídeos , Reprodutibilidade dos Testes , Neoplasias Gástricas/patologia
4.
Toxicology ; 304: 41-8, 2013 Feb 08.
Artigo em Inglês | MEDLINE | ID: mdl-23220562

RESUMO

Bleeding complications and delayed healing of gastric ulcer associated with use of clopidogrel is a common clinical concern; however, the underlying mechanisms remain to be determined. This study aimed to clarify whether clopidogrel could cause the damage of the human gastric epithelial cells and to further elucidate the mechanisms involved. After human gastric epithelial cell line GES-1 had been treated with clopidogrel (0.5-2.5 mM), the cell proliferation was examined by MTT assay, apoptosis was measured with DAPI staining and flow cytometry analysis, and the barrier function of the tight junctions (TJ) was evaluated by permeability measurement and transmission electron microscopy. Moreover, expression of the TJ proteins occludin and ZO-1 and the phosphorylation of the mitogen-activated protein kinases (MAPK) p38, ERK, and JNK were examined by western blot. In addition, three MAPK inhibitors specific to p38, ERK and JNK were used, respectively, to verify the signaling pathways responsible for regulating the expression of the TJ proteins being tested. Results showed that clopidogrel significantly increased dextran permeability, induced apoptosis, suppressed GES-1 cell viability, and reduced the expression of the TJ proteins (occludin and ZO-1), acting through p38 MAPK phosphorylation. Furthermore, these observed effects were partially abolished by SB-203580 (a p38 MAPK inhibitor), rather than by either U-0126 (an ERK inhibitor) or SP-600125 (a JNK inhibitor), suggesting that clopidogrel-induced disruption in the gastric epithelial cells is mediated by the p38 MAPK pathway. It is concluded that attenuated expression of the TJ proteins occludin and ZO-1 in human gastric epithelial cells could be involved in clopidogrel-induced gastric mucosal injury through activation of the p38 MAPK pathway.


Assuntos
Mucosa Gástrica/efeitos dos fármacos , Inibidores da Agregação Plaquetária/toxicidade , Ticlopidina/análogos & derivados , Junções Íntimas/efeitos dos fármacos , Proteínas Quinases p38 Ativadas por Mitógeno/metabolismo , Apoptose/efeitos dos fármacos , Western Blotting , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Clopidogrel , Relação Dose-Resposta a Droga , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/patologia , MAP Quinases Reguladas por Sinal Extracelular/metabolismo , Citometria de Fluxo , Mucosa Gástrica/patologia , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Proteínas Quinases JNK Ativadas por Mitógeno/metabolismo , Microscopia Eletrônica de Transmissão , Ocludina/genética , Fosforilação/efeitos dos fármacos , Inibidores da Agregação Plaquetária/administração & dosagem , Transdução de Sinais/efeitos dos fármacos , Ticlopidina/administração & dosagem , Ticlopidina/toxicidade , Junções Íntimas/metabolismo , Proteína da Zônula de Oclusão-1/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA